CONTE, PIERFRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.259
AS - Asia 9.740
EU - Europa 6.936
AF - Africa 2.435
SA - Sud America 1.955
OC - Oceania 265
Continente sconosciuto - Info sul continente non disponibili 125
Totale 56.715
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 33.896
SG - Singapore 2.855
HK - Hong Kong 1.859
CN - Cina 1.857
BR - Brasile 1.181
FI - Finlandia 974
IT - Italia 775
VN - Vietnam 709
SE - Svezia 673
DE - Germania 648
FR - Francia 493
PL - Polonia 473
RU - Federazione Russa 378
GB - Regno Unito 316
IN - India 198
NL - Olanda 167
UA - Ucraina 125
AT - Austria 120
KR - Corea 120
TR - Turchia 117
AR - Argentina 107
MX - Messico 102
IE - Irlanda 100
IQ - Iraq 96
CA - Canada 95
EC - Ecuador 92
CI - Costa d'Avorio 89
ID - Indonesia 89
JP - Giappone 86
PS - Palestinian Territory 86
AO - Angola 83
PE - Perù 83
CH - Svizzera 81
ES - Italia 80
GR - Grecia 80
IL - Israele 80
TN - Tunisia 80
AE - Emirati Arabi Uniti 79
CO - Colombia 78
RS - Serbia 78
BA - Bosnia-Erzegovina 77
BE - Belgio 77
CR - Costa Rica 77
MA - Marocco 76
BO - Bolivia 74
HN - Honduras 74
ZA - Sudafrica 74
CZ - Repubblica Ceca 73
GF - Guiana Francese 73
HU - Ungheria 73
LV - Lettonia 73
CL - Cile 72
AZ - Azerbaigian 71
BZ - Belize 71
UZ - Uzbekistan 71
YE - Yemen 71
AL - Albania 70
CG - Congo 70
CW - ???statistics.table.value.countryCode.CW??? 70
DO - Repubblica Dominicana 70
DZ - Algeria 70
GE - Georgia 70
GM - Gambi 70
MN - Mongolia 69
EE - Estonia 68
LB - Libano 68
LY - Libia 68
BB - Barbados 67
PA - Panama 67
UY - Uruguay 67
CM - Camerun 66
CU - Cuba 66
GT - Guatemala 66
JO - Giordania 66
LC - Santa Lucia 66
PY - Paraguay 66
MR - Mauritania 65
PH - Filippine 65
PK - Pakistan 65
JM - Giamaica 64
KG - Kirghizistan 64
MD - Moldavia 64
MZ - Mozambico 64
PR - Porto Rico 64
BS - Bahamas 63
GA - Gabon 63
PT - Portogallo 63
RO - Romania 63
YT - Mayotte 63
EG - Egitto 62
IR - Iran 62
LA - Repubblica Popolare Democratica del Laos 62
MK - Macedonia 62
TZ - Tanzania 62
ZM - Zambia 62
BW - Botswana 61
NI - Nicaragua 61
TH - Thailandia 61
VE - Venezuela 61
LU - Lussemburgo 60
Totale 53.721
Salva come PNG Salva come JPEG
Città #
Fairfield 5.856
Woodbridge 3.997
Houston 3.234
Ann Arbor 2.752
Ashburn 2.701
Cambridge 2.034
Seattle 2.027
Wilmington 1.885
Chandler 1.851
Hong Kong 1.789
Singapore 1.484
Boardman 875
San Diego 588
Princeton 578
Medford 576
Dong Ket 468
Des Moines 462
Helsinki 431
Bytom 392
Beijing 344
Nanjing 344
Munich 304
Santa Clara 297
Padova 247
Roxbury 166
Hefei 144
New York 110
Shenyang 109
Los Angeles 108
Hebei 100
São Paulo 100
Ho Chi Minh City 93
London 92
Nanchang 90
Jiaxing 84
Abidjan 83
Dublin 83
Guangzhou 76
Luanda 76
Seoul 71
Baku 68
Nuremberg 68
Tashkent 66
Ulan Bator 65
Amman 64
Nouakchott 63
San José 63
Castries 62
Vienna 62
Changsha 61
Lusaka 61
Panama City 61
Riga 61
Libreville 60
Nassau 60
Pune 60
Bridgetown 58
Dakar 58
Cayenne 57
Conakry 57
Managua 57
Tianjin 57
Antananarivo 55
Buffalo 55
Havana 55
Willemstad 55
Montevideo 53
Phnom Penh 53
Andorra la Vella 52
Bishkek 52
Kampala 51
Lima 50
Accra 49
Bamako 49
Maputo 49
Milan 49
Tbilisi 49
Harare 48
Mamoudzou 48
Tallinn 48
Vientiane 48
Chicago 47
Dar es Salaam 47
Redondo Beach 47
Turku 47
Addis Ababa 46
Noumea 46
Athens 45
Hanoi 45
Nairobi 45
Niamey 45
Podgorica 45
Sanaa 45
Dushanbe 44
Brazzaville 43
Gaborone 43
Kinshasa 43
Belgrade 42
Cotonou 42
Kingston 42
Totale 40.267
Salva come PNG Salva come JPEG
Nome #
0.1 grams of sub-cutaneous adipose tissue (SCAT) as source of adult multipotent mesenchymal stromal cells (MSC) for cell-based therapies. 394
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 305
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 269
211P: Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis 227
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 223
28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS) 216
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 215
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 210
A triple rare E709K and L833V/H835L EGFR mutation responsive to an irreversible pan-HER inhibitor: A case report of lung adenocarcinoma treated with afatinib 204
166P: Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series 202
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 195
Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer 195
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 194
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 192
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 189
Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman 186
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 185
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 184
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation 182
Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature 178
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time 177
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer 174
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 173
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 172
Non-Small Cell Lung Cancer in a Very Young Woman: A Case Report and Critical Review of the Literature 171
Immune characterization of breast cancer metastases: Prognostic implications 170
Ribociclib as first-line therapy for HR-positive, advanced breast cancer 167
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 166
77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC) 164
Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists 164
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 162
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 161
Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment 160
Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model 159
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter? 158
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 157
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 157
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 156
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 155
In response to Jackson letter to the editor regarding safety of intravenous and oral bisphosphonates and compliance with dosing regimens 154
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 151
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 150
Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy 149
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 148
LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab 148
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE 147
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 146
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 145
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 145
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 145
A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology 143
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer 143
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 143
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 141
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 141
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 140
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 140
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 138
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 138
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 138
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 138
Olaparib for the treatment of breast cancer 137
Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer 136
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 136
Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment? 135
MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: Correlation with pathological and clinical data 135
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 135
Evolution of HER2-low expression from primary to recurrent breast cancer 135
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 134
Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology 134
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 134
Achievements and unmet needs in the management of advanced ovarian cancer 133
Squamous cell carcinomas of the lung and of the head and neck: New insights on molecular characterization 133
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 133
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 131
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 131
Effects of sulfonylureas on tumor growth: A review of the literature 130
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study 129
Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry 128
Rare breast cancer subtypes: histological, molecular, and clinical peculiarities 128
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer 128
Use of scalp-cooling device to prevent alopecia for breast cancer patients receiving chemotherapy: a single-Institution prospective study 128
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 128
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 127
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 126
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 126
A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. 125
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 124
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study. 124
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 124
Fat grafting for breast cancer patients: From basic science to clinical studies 123
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 123
Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. 122
Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety 122
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 122
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel 122
Critical review about MDM2 in cancer: Possible role in malignant mesothelioma and implications for treatment 121
HER2-Positive Early Breast Cancer 121
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 121
Epirubicin plus paclitaxel regimen as second-line treatment of patients with small-cell lung cancer 119
Totale 15.642
Salva come PNG Salva come JPEG
Categoria #
all - tutte 189.580
article - articoli 184.427
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 584
patent - brevetti 518
selected - selezionate 0
volume - volumi 2.712
Totale 377.821
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214.545 0 0 183 292 263 538 353 446 613 462 572 823
2021/20227.498 257 976 991 545 436 388 523 715 322 223 622 1.500
2022/20234.395 1.028 290 114 482 795 483 24 273 573 56 204 73
2023/20242.112 142 277 220 142 138 241 120 102 75 69 298 288
2024/20259.467 40 677 532 268 1.313 234 460 845 943 319 1.422 2.414
2025/202611.175 997 3.984 6.194 0 0 0 0 0 0 0 0 0
Totale 57.119